ADMA Biologics Reports Third-Quarter 2026 Revenue of $141.1 Million
Net income was $49.88 million and diluted EPS was $0.22, up 36.9% and 46.7%, respectively, from the prior-year quarter. Revenue rose 5.1%.
Related stories
Oceanagold Reports Quarterly Revenue of $149.1 Million
M impact | EQUITY | Nov 05, 2026, 12:11 AM UTC
Kakao Plans KRW 150 Billion Share Cancellation
Kakao plans to cancel shares worth KRW 150 billion.
M impact | EQUITY | Nov 05, 2026, 12:10 AM UTC
Toyota Motor shares rise 7.4%
M impact | EQUITY | Nov 05, 2026, 12:06 AM UTC
Global market picture: S&P 500 +1.65%, Nasdaq 100 +0.72%; EUR/USD +0.41%, WTI -8.05%
Global market picture. US index futures: S and P futures is up 1.65 percent, Nasdaq futures is up 0.72 percent, Dow futures is up 3.14 percent and Russell futures is up 1.48 percen
M impact | EQUITY | Nov 05, 2026, 12:06 AM UTC
South Korea’s KOSPI falls 2%
M impact | EQUITY | Nov 05, 2026, 12:05 AM UTC
KOSPI falls 2%
M impact | EQUITY | Nov 05, 2026, 12:05 AM UTC